CAPTRUST Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$959K Buy
23,795
+14,373
+153% +$537K ﹤0.01% 1640
2025
Q4
$328K Sell
9,422
-1,426
-13% -$112K ﹤0.01% 2180
2025
Q3
$902K Buy
10,848
+2,717
+33% +$197K ﹤0.01% 1485
2025
Q2
$597K Sell
8,131
-1,001
-11% -$72.6K ﹤0.01% 1624
2025
Q1
$1.04M Sell
9,132
-104,856
-92% -$6.38M ﹤0.01% 1246
2024
Q4
$5.74M Buy
113,988
+10,248
+10% +$537K 0.02% 501
2024
Q3
$4.8M Sell
103,740
-19,255
-16% -$684K 0.01% 542
2024
Q2
$4M Sell
122,995
-6,676
-5% -$183K 0.01% 562
2024
Q1
$3.27M Sell
129,671
-12,401
-9% -$293K 0.01% 624
2023
Q4
$4.61M Sell
142,072
-908
-0.6% -$24.9K 0.02% 585
2023
Q3
$3.9M Sell
142,980
-85,187
-37% -$2.47M 0.01% 606
2023
Q2
$5.08M Buy
228,167
+621
+0.3% +$14.3K 0.02% 502
2023
Q1
$4.93M Buy
227,546
+208,844
+1,117% +$4.58M 0.02% 464
2022
Q4
$380K Buy
18,702
+147
+0.8% +$3.69K ﹤0.01% 1488
2022
Q3
$476K Buy
18,555
+10,923
+143% +$292K ﹤0.01% 1275
2022
Q2
$181K Buy
7,632
+827
+12% +$18K ﹤0.01% 1758
2022
Q1
$153K Buy
6,805
+3,181
+88% +$67.7K ﹤0.01% 1924
2021
Q4
$72K Buy
3,624
+256
+8% +$5.19K ﹤0.01% 2389
2021
Q3
$66K Buy
3,368
+37
+1% +$774 ﹤0.01% 2390
2021
Q2
$73K Sell
3,331
-644
-16% -$14.3K ﹤0.01% 2249
2021
Q1
$95K Buy
3,975
+3,755
+1,707% +$100K ﹤0.01% 1995
2020
Q4
$6K Buy
220
+100
+83% +$2.11K ﹤0.01% 2762
2020
Q3
$2K Buy
+120
New +$1.91K ﹤0.01% 2745

Other funds holding CORT

CAPTRUST Financial Advisors's CORT Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Corcept Therapeutics (CORT) stake by 153% in Q1 2026, buying an estimated $537K and bringing the position to 23,795 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #1640.

CAPTRUST Financial Advisors first reported a position in CORT in Q3 2020 and has held it in 23 quarters since. The position peaked at $5.74M in Q4 2024. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • CAPTRUST Financial Advisors held 23,795 shares of Corcept Therapeutics worth $959K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 14,373 Corcept Therapeutics shares in Q1 2026, an estimated $537K.
  • Corcept Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1640 holding.
  • CAPTRUST Financial Advisors first reported a position in Corcept Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • CAPTRUST Financial Advisors's Corcept Therapeutics position peaked at $5.74M in Q4 2024.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.